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Abstract
Since 2013, the International Union of Immunological Societies (IUIS) expert committee (EC) on Inborn Errors of Immunity
(IEI) has published an updated phenotypic classification of IEI, which accompanies and complements their genotypic classifi-
cation into ten tables. This phenotypic classification is user-friendly and serves as a resource for clinicians at the bedside. There
are now 430 single-gene IEI underlying phenotypes as diverse as infection, malignancy, allergy, autoimmunity, and
autoinflammation. We herein report the 2019 phenotypic classification, including the 65 new conditions. The diagnostic algo-
rithms are based on clinical and laboratory phenotypes for each of the ten broad categories of IEI.
Keywords IUIS . primary immune deficiency . inborn errors of immunity . immune dysregulation . autoinflammatory disorders .
classification
Introduction
Human inborn errors of immunity (IEI) are caused bymonogenic
germline mutations resulting in loss or gain of function of the
encoded protein. They can be dominant or recessive, autosomal
or X-linked, and with complete or incomplete penetrance. They
manifest as increased susceptibility to a broad or narrow spec-
trum of infectious diseases, as well as a growing diversity of
autoimmune, autoinflammatory, allergic, and/or malignant phe-
notypes. They now comprise 406 distinct disorders with 430
different gene defects listed in the 2019 International Union of
Immunological Societies (IUIS) classical classification [1]. If
most IEI are individually rare, they are collectively more com-
mon than generally thought [2].
The (IUIS) expert committee on IEI proposes every other
year a genotypic classification of all these disorders [1], which
facilitates both research on, and diagnosis of, these conditions
worldwide. This classification is organized in ten tables, each
of which groups IEI sharing a given pathogenesis. However,
with the growing number of IEI included in this catalog, these
tables are not always easy to use at the bedside. We thus
reported from 2013 onward a more user-friendly classification
adapted for the clinician, based on the clinical and laboratory
features observed in these patients. This phenotypic classifi-
cation proved to be as popular as the genotypic classification
(15 k vs 12 k downloads on publisher site) [3] and has been
adapted in a smartphone application [4].
Here, we present an update of the phenotypic classi-
fication of IEI, based on the 2019 IEI classical classifi-
cation [1]. This tree-based decision-making process is
aimed to physicians, regardless of their familiarity with
IEI. It aims at helping them to reach a diagnosis based
on simple clinical and biological phenotypes.
Methodology
We included in our figures all disorders indexed in the
2019 update of the IUIS IEI classification [1]. A phe-
notypic algorithm was assigned to each of the ten main
groups of the classification and the same color was used
for each group of similar conditions. Given the high
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number of diseases, several categories have been split
since last update [3] in two sub-figures to be more
informative.
Disease names are presented in red and genes in bold italic.
An asterisk is added to highlight extremely rare disorders (less
than 10 reported cases to date). However, the reader should
keep in mind that some genes have been very recently de-
scribed and that true prevalence is unknown. A double asterisk
is added when only one case or one kindred has been reported
to date. In these cases, it is difficult to confirm than observed
phenotype would be reproducible in other patients carrying
the same defect, or if it is an exception.
Results
Algorithms for the 2019 update of IUIS phenotypical classifi-
cation are presented in Figs. 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10.
Discussion
These algorithms are aimed to guide clinicians to diag-
nose patients presenting typical phenotype. However,
readers should be aware of the limitations of such a
work.
More and more reports show a spectrum of atypical
presentations related to hypomorphic mutations of
those genes. Omenn syndrome (OMIM #603554) is a
good example of such an atypical presentation, as
well as “leaky SCID” and RAG deficiency spectrum
[5].
Moreover, readers should be extremely cautious
with descriptions of disease when only one patient
or kindred have been reported. We are aware that
these reports may not reflect the typical phenotype
of such defects, but the exception; however, we
thought that it was needed to be mentioned in these
classifications.
Fig. 1 Immunodeficiencies affecting cellular and humoral immunity. a
Severe combined immunodeficiencies defined by T cell lymphopenia. b
Combined immunodeficiencies. * T cell lymphopenia in SCID is defined
by CD3+ T cells < 300/μL. AD autosomal dominant transmission, ADA
adenosine deaminase, Adp adenopathies, Ag antigen, AR autosomal
recessive transmission, β2m bêta-2 microglobulin, Bc B cells, CBC
complete blood count, CD cluster of differentiation, CVID common
variable immunodeficiency, def deficiency, EBV Epstein-Barr virus, Eo
eosinophilia, GOF gain-of-function mutation, HHV8 human herpes virus
8, HIGM hyper IgM syndrome, HPV human papillomavirus, HSM
hepa tosp lenomega ly, Ig immunoglobu l in s , MHC major
histocompatibility complex, Nl normal, NK natural killer, SCID severe
combined immunodeficiency, Tc T cells, TCR T cell receptor, Treg
regulatory T cells, XL X-linked transmission
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Jacobsen Sd. 11q23del. 
Recurrent respiratory infecons; 
mulple warts; facial 
dysmorphism, growth
retardaon. Lymphopenia, Low
NK, Bc and switched memory Bc. 
Hypogammaglobulinemia.
Ataxia telangiectasia. ATM: Ataxia; telangiectasia; pulmonary infecons; lymphorecular and other malignancies; increased α-
fetoprotein;  increased radiosensivity, chromosomal instability and translocaons. Oen decreased IgA, IgE and IgG subclasses; 
increased IgM; anbodies variably decreased. Tc : Progressive decrease, abnormal prolif to Mitogens. 
IIa. CID with associated or syndromic features
Carlage Hair Hypoplasia RMRP. 
Short-limbed dwarfism with 
metaphyseal dysostosis, sparse 
hair, bone marrow failure; 
autoimmunity; suscepbility to 
lymphoma and other cancers; 
impaired spermatogenesis; 
neuronal dysplasia of the 
intesne. Ig: Nl or ↓. Tc: Varies 
from  ↓↓ (SCID) to Nl; impaired 
lymphocyte proliferaon. 
Schimke Sd SMARCAL1
Short stature, spondilo-
epiphyseal dysplasia, IUGR; 
nephropathy; bacterial, viral, 
fungal infecons; may present as 
SCID; bone marrow failure. Tc: ↓
Thymic
Defects with 
Addional 
Congenital 
Anomalies
Congenital thrombocytopenia
Bloom sd. BLM.Short stature; bird like face; sun-sensive erythema; marrow failure; leukemia; lymphoma; chromosomal instability. Low Ig. 
PMS2 def. PMS2. Café-au-lait spots ; lymphoma, colorectal carcinoma, brain tumors. HIGM and abnormal anbody responses. Reduced  
Bc, switched and non-switched. 
Immunodeficiency with centromeric instabily and facial anomalies: ICF1. DNMT3B;  ICF2:ZBTB24;  ICF3:CDCA7;  ICF4:HELLS.Facial 
dysmorphism; macroglossia; bacterial/opportunisc infecons; malabsorpon; malignancies. Cytopenias; mulradial configuraons of 
chromosomes 1,9,16; no DNA breaks. Ig: Hypogammaglobulinemia; Tc and Bc: decreased or Nl. 
RNF168 def* (RIDDLE sd). RNF168. Short stature; mild defect of motor control to ataxia; normal intelligence to learning difficules; mild 
facial dysmorphism to microcephaly;  increased radiosensivity. Low IgG or IgA. 
DNA Repair Defects other than those listed in Table1:  Karyotype
XL: Wisko Aldrich Sd or XL thrombocytopenia WAS (LOF). Recurrent bacterial and viral infecons; bloody diarrhea;  eczema; 
lymphoma; autoimmune disease; IgA nephropathy; vasculis. Small platelets; Decreased IgM. Low anbody to polysaccharides; 
oen increased IgA and IgE. Nl Bc.  Tc: Progressive decrease in numbers; Low Tc responses to an-CD3. 
Paents with XL-thrombocytopenia have later onset of complicaons and more favourable life expectancy but eventually
develop similar complicaons as observed in WAS
AR:  WIP deficiency*. WIPF1, WAS protein absent. +/- small platelets; increased IgE. Bc : Nl to low. Tc: Reduced; defecve 
lymphocyte responses to an-CD3.
AR: Defecve Arp2/3-mediated filament branching.  ARPC1B. Recurrent invasive infecons, colis, vasculis. Mild 
trombocytopenia, normal sized platelets; autoanbodies (ANA, ANCA); eosinophilia.High IgA and IgE.
AD. Hypoparathyroidism, 
conotruncal cardiac 
malformaon, velopalatal
insufficiency, facial dysmorphism, 
intellectual disability . Ig : Normal 
or decreased. Tc: ↓or Nl May 
have low TRECs at NBS.
DiGeorge/velocardiofacial
Sd. Chr22q11.2 deleon Sd. 
22q11.2DS. 
TBX1 deficiency . TBX1 
MCM4 def. MCM4. Viral infecons:EBV,HSV,VZV.short stature.Bc lymphoma; Adrenal failure; NKc low number and funcon. 
AD. CHARGE Sd. CHD7, 
SEMA3E.                    Coloboma, 
heart anomaly, choanal atresia, 
intellectual disability, genital and 
ear anomalies; CNS 
malformaon; some are SCID-like 
and have low TRECs. Ig: Normal 
or decreased. Tc: Decreased or 
normal; response to PHA may be 
decreasedPOLE1 (Polymerase ε subunit 1) deficiency (FILS syndrome). POLE1.Recurrent respiratory infecons; meningis; facial dysmorphism, 
livido, short stature. Low IgM, lack of anbody to PPS. Low memory Bc. Decreased Tc proliferaon. 
POLE2 (Polymerase ε subunit 2) deficiency**. POLE2. Recurrent infecon, disseminated BCG infecons, autoimmunity (type 1 diabetes, 
hypothyroidism), facial dysmorphism;  Low Ig; Very low Bc. Lymphopenia, lack of TRECS, absent proliferaon of angens. 
Ligase I deficiency *. LIGI Recurrent bacterial and viral infecons;  growth retardaon; sun sensivity; lymphoma; radiaon sensivity. 
Macrocyc red blood cells. Hypogammaglobulinemia. Reduced Ab response. Lymphopenia, increased γδTc, decreased mitogen response.
Nijmegen breakage Sd. NBS1. Microcephaly; bird-like face; lymphomas; solid tumors;  increased radiosensivity; chromosomal instability. 
Oen decreased IgA, IgE and IgG subclasses;increased IgM; anbodies variably decreased. Bc: Variably reduced. Tc: progressive decrease.
NSMCE3 deficiency*. NSMCE3. Severe lung disease (possibly viral); thymic hypoplasia, Chromosomal breakage; radiaon sensivity. Ig: 
Decreased Ab responses to PPS,  normal IgG, IgA, normal to elevated IgM. Tc : Low, poor responses to mitogens and angens.
Immuno-
osseous
dysplasias
GINS1 def*. GINS1. IUGR. Neutropenia, NK cells very low. Tc and Bc: low or normal. High IgA, Low IgG and IgM. 
Immunoskeletal dysplasia
with neurodevelopmental
abnormalies. EXTL3. Short 
stature; cervical spinal stenosis,
neurodevelopmental 
impairment. Eosinophilia; Ig: 
variably ↓ Tc:  ↓
MOPD1 Deficiency. 
RNU4ATAC.Recurrent bacterial 
infecons, lymphadenopathy, 
Spondyloepiphyseal dysplasia, 
IUGR, renal dystrophy, facial 
dysmorphism; +/- microcephaly. 
short stature.  Ig: ↓ , specific 
anbodies variably  decreased
MYSM1 def* MYSM1,  AR
Short stature,  congenital bone 
marrow failure, myelodysplasia. 
Skeletal anomalies; cataracts;  
developmental delay. Affects 
granulocytes. Bc: immature. Tc: 
lymphopenia, reduced naïve Tc. 
Hypogammaglobulinemia
Chromosome 10p13-p14 
deleon Syndrome.              
10p13-p14DS. AD.
Hypoparathyroidism; renal
disease; deafness; growth 
retardaon; facial dysmorphism; 
cardiac defects may be present
FOXN1 haploinsufficiency. 
FOXN1, AD
Recurrent, viral and bacterial 
respiratory tract infecons; skin 
involvement (eczema, dermas), 
nail dystrophy. T cell lymphopenia
may normalize by adulthood. 
BMFS2 (Hebo def). ERCC6L2,  AR. Facial dysmorphism; microcephaly, learning difficules. Bone marrow failure.
Fig. 2 a, b CID with associated or syndromic features. Ab antibody, AD
autosomal dominant transmission, AD DN autosomal dominant
transmission with dominant negative effect, ANA anti-nuclear
antibodies, ANCA anti-neutrophil cytoplasm antibodies, AR autosomal
recessive transmission, Bc B cells, BCG bacillus Calmette-Guerin, BCR
B cell receptor, CD cluster of differentiation, CID combined
immunodeficiency of T and B cells, CMV cytomegalovirus, CNS
central nervous system, def deficiency, DNA deoxyribonucleic acid,
EBV Epstein-Barr virus, EDA anhidrotic ectodermal dysplasia, GOF
gain-of-function, HIES hyper IgE syndrome, FILS facial dysmorphism,
immunodeficiency, livedo and short stature, ID immunodeficiency, Ig
immunoglobulins, IL-6 interleukin-6, IUGR intrauterine growth
retardation, LOF loss-of-function, MCC mucocutaneous candidiasis, Nl
normal, NK natural killer, PHA phytohemagglutinin, PPS
polysaccharides, SCID severe combined immunodeficiency, sd
syndrome, Tc T cells, TCR T cell receptor, TREC T cell receptor
excision circle, XL X-linked transmission
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IIb. CID with associated or syndromic features
Hyper-IgE syndromes (HIES)
AD-HIES (Job sd ). STAT3, AD LOF. Disncve facial features (broad 
nasal bridge); bacterial infecons (boils and pulmonary abscesses, 
pneumatoceles) due to S. aureus, Aspergillus, Pneumocyss jirovecii; 
eczema; mucocutaneous candidiasis; hyperextensible joints, 
osteoporosis and bone fractures, scoliosis, retenon of primary 
teeth;  aneurysm formaon. IgE ↑↑; specific anbody producon↓. 
Bc:Normal;  reduced switched and non-switched memory Bc; BAFF 
expression ↑. Tc:Nl overall; Th-17 & T-follicular helper cells ↓
Comel Netherton Sd; SPINK5; Congenital ichthyosis, bamboo 
hair,atopic diathesis; ↑ bacterial infecons, failure to thrive. ↑ IgE 
and IgA;  Other Ig: variably decreased. Bc: Switched and non-switched 
Bc are↓.                  
PGM3 deficiency. PGM3. Severe atopy; autoimmunity; skeletal
anomalies: short stature, brachydactyly, dysmorphic facial
features. Recurrent pneumonia, recurrent skin abscesses,bacterial 
and viral infecons; cognive impairment; delayed CNS myelinaon
in some. Ig:Nl or elevated. Elevated IgE; eosinophilia. Reduced B and 
memory Bc. CD8 and CD4 Tc may be↓.
Purine nucleoside phosphorylase deficiency.  PNP. Autoimmune 
haemolyc anemia, neurological impairment. Hypouricemia. Ig : Nl/Low.  
Bc: Nl. Tc: Progressive decrease
Hepac veno-occlusive disease with immunodeficiency (VODI). SP110. 
Hepac veno-occlusive disease, Pneumocyss jirovecii pneumonia, CMV, 
candida, thrombocytopenia, hepatosplenomegaly, cerebrospinal 
leukodystrophy. Decreased IgG, IgA, IgM, absent germinal centers and 
ssue plasma cells. Decreased memory Bc . Decreased memory Tc.
Vici syndrome. EPG5. Agenesis of the corpus callosum, cataracts, cardiomyopathy, skin hypopigmentaon,  intellectual disability, microcephaly, CMC. 
Ig: Decreased IgG2. Bc: Defecve. Profound depleon of CD4+ cells.
Defects of Vitamin 
B12 and Folate
Metabolism:
Anhidroc
Ectodermodysplasia
with ID
Bacterial infecons, autoinflammaon, amylopecnosis.Bc: Nl,decreased memory Bc.
HOIL1 deficiency. RBCK1. Poor Ab responses to polysaccharides. HOIP deficiency*. RNF31. Lymphangiectasia. Ig: decreased. 
Calcium Channel Defects. Autoimmunity, EDA, non-progressive myopathy. 
Ig and Bc: Nl. Tc: Normal, defecve TCR mediated acvaon. ORAI-1 
deficiency*. ORAI1 . STIM1 deficiency*. STIM1
Hennekam-lymphangiectasia-lymphedema syndrome*. CCBE1, FAT4. 
Lymphangiectasia and lymphedema with facial abnormalies and other 
dysmorphic features. Ig: decreased. Bc and Tc: Variable. 
Kabuki Sd. KMT2D (MLL2): AD. KDM6A: XL.
Typical facial abnormalies, cle or high arched palate, skeletal abnormalies, short stature, intellectual disability, congenital heart defects, recurrent 
infecons (os media, pneumonia) in 50% of paents. Autoimmunity may be present. Low IgA and occasionally  low IgG. 
ZNF341 deficiency. ZNF341.  AR. Phenocopy of AD-HIES: Mild facial 
dysmorphism, early onset eczema, MCC, bacterial skin infecons, 
abscesses, recurrent bacterial respiratory infecons (S. aureus), lung 
abscesses and pneumatoceles, hyperextensible joints, bone fractures 
and retenon of primary teeth
ERBIN deficiency**. ERBB21P.   Recurrent respiratory infecons, 
suscepbility to S. aureus, eczema, hyperextensible joints, scoliosis, 
arterial dilataon in some. Moderately increased IgE; increased Treg.
IL6ST deficiency*. IL6ST.  Bacterial infecons, boiles, eczema, 
pulmonary abscesses, pneumatoceles, bone fractures, scoliosis, 
retenon of primary teeth, craniosynostosis. ↓B-cell memory.
Loes-Dietz syndrome. TGFBR1, TGFBR2. Recurrent respiratory 
infectons, eczema, food allergies, hyperextensible joints, scoliosis, 
retenon of primary teeths; aorc aneurisms.
Immunodeficiency, developmental delay and hypohomocysteinemia, IMDDHH*. Acvang de-novo mutaons in NFE2L2. AD. Recurrent respiratory 
and skin infecons, growth retardaon, developmental delay; white maer cerebral lesions, decreased level of homocysteine; increased expression of 
stress response genes. Hypogammaglobulinemia. Bc: Decreased switched-memory Bc. 
Tricho-Hepato-Enteric syndrome. TTC37; SKIV2L* . Respiratory infecons, IUGR, wooly hair, early onset intractable diarrhea, liver cirrhosis, platelet 
abnormalies. Impaired IFNγ producon, Hypogammaglobulinemia, low anbody responses. Bc: Variably low switched-memory Bc.
IL6R deficiency*. IL6R.  Recurrent pyogenic infecons, cold
abscesses, high circulang IL-6 Levels.
CID with early-onset asthma, eczema and food allergies, 
autoimmunity ID with atopic dermas (CADINS)*. CARD11. AD LOF.  
Variable atopy, cutaneous viral infecons, recurrent respiratory
infecons, lymphoma. Eosinophilia, ↓Tc proliferaon. Nl to low Bc.
Anhidroc ectodermal
dysplasia,various infecons 
(bacteria, mycobacteria, viruses and 
fungi), colis, variable defects of 
skin, hair and teeth. 
NEMO deficiency. IKBKG (NEMO).
XL, monocyte dysfuncon. Ig
decreased, some with elevated IgA, 
IgM, poor specific anbody 
responses, absent anbody to 
polysaccharide angens. Bc: Nl, Low 
memory and isotype switched Bc. 
Tc: Nl/decreased, TCR acvaon 
impaired. 
EDA-ID due to IKBA GOF mutaon. 
NFKBIA (IKBA). AD Tc and 
monocyte dysfuncon Decreased 
IgG and IgA, elevated IgM, poor 
specific anbody responses, absent 
anbody to polysaccharide 
angens. Normal Bc numbers, 
impaired BCR acvaon, low 
memory and isotype switched Bc. 
Normal total Tc, TCR acvaon 
impaired. 
EDA-ID due to IKBK GOF mutaon* 
IKBB. AD. Low Tc. Bc: Nl number, 
poor funcon. Low Ig.
BCL11B deficiency. BCL11B. AD. Congenital abnormalies: neonatal teeth, 
dysmorphic facies; absent corpus callosum; neurocognive deficits. Tc : 
Low, poor proliferaon. 
STAT5b deficiency. STAT5B. AR. Growth-hormone insensive dwarfism, 
dysmorphic features, eczema, lymphocyc intersal pneumonis, 
autoimmunity. Hypergammaglobulinemia, High IgE.
AD DN: Growth failure and eczema only. High IgE.
ID with mulple intesnal atresias. TTC7A . Bacterial (sepsis), fungal, viral 
infecons, mulple intesnal atresias, oen with intrauterine 
polyhydramnios and early demise, some with SCID phenotype. Markedly 
decreased IgG, IgM, IgA. Bc:Nl/low.Tc: Variable/absent, low TRECs (may 
present with SCID at birth)
Wiedemann-Steiner Sd. KMT2A (MLL): AD Respiratory infecons; short stature; hypertelorism; hairy elbows; developmental delay, intellectual
disability. Hypogammaglobulinemia, decreased memory Bc.
Megaloblasc anemia, Ig: 
decreased. 
Transcobalamin 2 
deficiency. TCN2. 
pancytopenia, if untreated for 
prolonged periods results in 
intellectual disability. 
Deficiency causing 
hereditary folate
malabsorbon. SLC46A1. 
failure to thrive, if untreated 
for prolonged periods results 
in intellectual disability
Methylene-
tetrahydrofolate
dehydrogenase 1 
deficiency MTHFD1.
Recurrent bacterial infecon, 
Pneumocyss jirovecii; failure 
to thrive;  neutropenia; 
seizures, intellectual
disability; folate-responsive
↓ Bc, ↓ anbody responses 
to conjugated polysaccharide 
angens. 
Fig. 2 (continued)
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F i g . 3 P r e d o m i n a n t l y a n t i b o d y d e f i c i e n c i e s . a
Hypogammaglobulinemias. b Other antibody deficiencies. AD
autosomal dominant transmission, AR autosomal recessive
transmission, Bc B cells, BENTA B cell expansion with NF-κB and T
cell anergy, CD cluster of differentiation, CMF flow cytometry, COPD
chronic obstructive pulmonary disease, def deficiency, EBV Epstein-Barr
virus, GOF gain-of-function, Hx patient history, Ig immunoglobulins, Nl
normal, XL X-linked transmission
72 J Clin Immunol (2020) 40:66–81
III. Predominantly Antibody deficiencies.   
b: Other Anbody deficiencies
Severe Reducon in Serum IgG and IgA with 
Normal or elevated IgM
and Normal Numbers of Bc :  
Hyper IgM Syndromes 
AID deficiency. 
AICDA. AR or AD.
Bacterial infecons,  enlarged lymph nodes and germinal 
centers.  Nl memory Bc, but lacking somac 
hypermutaon in AR form.
UNG deficiency. UNG. 
Enlarged lymph nodes and germinal centers. 
INO80 def*. INO80 . 
Severe bacterial infecons.
MSH6*. MSH6 . 
Family or personal history of cancer. Variable IgG, 
defects, increased IgM in some, Nl Bc, low switched 
memory Bc. 
Isotype, Light Chain, or Funconal Deficiencies                                                                              
with Generally Nl Numbers of Bc
Ig heavy chain mutaons and deleons.
Mutaon or chromosomal deleon at 14q32. 
May be asymptomac. One or more IgG and/or IgA subclasses as well as IgE may be absent.
Kappa chain deficiency*.  IGKC. 
Asymptomac. All immunoglobulins have lambda light chain.
Isolated IgG subclass deficiency.  Unknown. 
Usually asymptomac, a minority may have poor anbody response to specific angens and recurrent 
viral/bacterial infecons. Reducon in one or more IgG subclass.
IgG subclass deficiency with IgA deficiency. Unknown. 
Recurrent bacterial infecons. May be asymptomac. Reduced 
IgA with decrease in one or more IgG subclass. 
Selecve IgA deficiency. Unknown. 
May be asymptomac. Bacterial infecons, autoimmunity 
mildly increased. Very low to absent IgA with other isotypes
normal, normal subclasses and specific anbodies. 
Specific anbody deficiency with normal Ig levels and normal B cells.  Unknown. 
Reduced ability to produce anbodies to specific angens. Ig: Nl.
Transient hypogammaglobuliemia of infancy. Unknown. 
Usually not associated with significant infecons, normal ability 
to produce anbodies to vaccine angens. IgG and IgA decreased. 
CARD11 GOF .                          
CARD11. AD.  BENTA syndrome
Splenomegaly,                                    
lymphadenopathy,                          
poor vaccine responses. 
Selecve IgM deficiency. Unknown. Pneumococcal / bacterial infecons. Absent serum IgM. 
High Bc numbers due to
constuve NF-κB acvaon 
Fig. 3 (continued)
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XL magnesium EBV and neoplasia (XMEN)*. MAGT1.XL. EBV infecon, lymphoma, viral
infecons, respiratory and GI infecons. Glycosylaon disorder. Some paents can present with
neurological manifestaons. Low CD4 Low recent thymic emigrant cells, poor proliferaon to CD3.
High B cells, high DN T cells..
Fever, HSM, cytopenias, 
Nl Bc. Increased activated Tc. 
Decreased to absent NK and CTL 
activities (cytotoxicity and/or 
degranulation)
Perforin deficiency (FHL2).PRF1.
UNC13D / Munc13-4 deficiency (FHL3). 
UNC13D. 
Syntaxin 11 deficiency (FHL4). STX11. 
STXBP2 / Munc18-2 deficiency (FHL5) 
STXBP2.  Enteropathy
Familial Hemophagocytic
Lymphohistiocytosis
Syndromes:
IV. Diseases of immune dysregulaon.
a : Hemophagocyc Lymphohisocytosis HLH  &  EBV suscepbility
Chediak Higashi Sd. LYST
Recurrent infections, fever, HSM, bleeding
tendency, progressive neurological
dysfunction. Giant lysosomes (WBC),
neutropenia, cytopenias, Specific hair
shaft anomaly. Increased activated Tc.
Griscelli Sd type 2. RAB27A.
Fever, HSM, cytopenias; Specific hair
shaft anomaly
Hermansky Pudlak sd type 2. AP3B1.
Recurrent infections, pulmonary fibrosis,
increased bleeding, neutropenia; Specific
hair shaft anomaly.
Hypopigmentation: 
Partial albinism . Decreased NK and CTL 
activities(cytotoxicity and/or degranulation). Bc
and Tc: Nl
Hermansky-Pudlak syndrome, type 10**.
AP3D1.
Oculocutaneous albinism, severe
neutropenia, recurrent infections, seizures,
hearing loss and neurodevelopmental
delay .
FAAP24 deficiency**. FAAP24.
EBV-driven lymphoproliferative disease.
Increased activated Tc. Failure to kill
autologous EBV transformed Bc. Nl NK
cell function.
Hemophagocyc Lymphohisocytosis (HLH)
XL, XLP2. XIAP.
Splenomegaly, lympho-
proliferation, Colitis, IBD, 
hepatitis. 
Hypogammaglobulinemia, Low
iNKT cells. Increased T cells
susceptibility to apoptosis to
CD95 and enhanced activation-
induced cell death (AICD).
Normal NK and CTL cytotoxic
activity. XIAP def (FCM)
XL, XLP1. SH2DIA.
Clinical and immunologic
features triggered by EBV
infection:
lymphoproliferation, Aplastic
anemia, Lymphoma.
Hypogammaglobulinemia,
Absent iNKT cells. Impaired NK
cell and CTL cytotoxic activity .
Reduced Memory B cells .
SAP deficiency (FCM).
EBV associated HLH
AR, CD27 deficiency .            
CD27 (TNFRSF7).      
Features triggered by EBV 
infection, aplastic anemia, 
low  iNKTc lymphoma. Low Ig
Suscepbility to EBV 
CTPS1 deficiency. CTPS1.
Recurrent/chronic bacterial and viral 
infecons (EBV, VZV), EBV lympho-
proliferaon, B cell non-Hodgkin 
lymphoma. Tc: poor proliferaon to Ag
RLTPR (CARMIL2) deficiency. RLTPR.
Recurrent bacterial, fungal and
mycobacterial infecons, viral warts,
molluscum and EBV lymphoproliferave and
other malignancy, atopy. Ig Nl to ↓, poor T
dependent anbody response. Nl Bc. Tc: ↓ Treg,
high CD4, poor funcon.
CD70 deficiency*. CD70 (TNFSF7).
Hodgkin lymphoma, autoimmunity in
some paents. Reduced IgM, IgG, IgA
(75%) and reduced Ag-specific Ab
responses (50%). Bc:poor anbody and
memory responses. Tc:low Treg, poor
acvaon and funcon
PRKCD deficiency*. PRKCD. Recurrent infecons, EBV chronic infecon, lymphoproliferaon,
SLE-like autoimmunity (nephroc and anphospholipid Sd). Low IgG. Low memory Bc high CD5 Bc
SLC7A7 deficiency. SLC7A7.
Lysinuric protein intolerance, bleeding
tendency, alveolar proteinosis Hyper-
inflammatory  response of macrophages. Nl
Tc and NK cell function
CD137 deficiency*. TNFRSF9. EBV 
lymphoproliferaon, B cell lymphoma, 
chronic acve EBV infecon. Low IgA and 
IgG, poor response to angens, decreased T 
cell proliferaon
RASGRP1 deficiency*. RASGRP1.
Recurrent pneumonia, herpes virus
infecons, EBV associated lymphoma.
Decreased NK cell funcon; high IgA. Bc
and Tc: Poor acvaon, proliferaon,
molity
Fig. 4 Diseases of immune dysregulation. a Hemophagocytic
lymphohistiocytosis. b Other diseases of immune dysregulation. Ab
antibody, AD autosomal dominant transmission, Ag antigen, AIHA
autoimmune hemolytic anemia, ALPS autoimmune lymphoproliferative
syndrome, APS autoimmune polyendocrinopathy syndrome, AR
autosomal recessive transmission, Bc B cells, CD cluster of
differentiation, CMF flow cytometry, CTL cytotoxicT lymphocytes, def
deficiency, DNT double negative T cells, EBV Epstein-Barr virus, FHL
familial hemophagocytic lymphohistiocytosis, GOF gain-of-function,
HLH h emo p h a g o c y t i c l ym p h o h i s t i o c y t o s i s , ( H ) SM
(hepato)splenomegalia, IBD inflammatory bowel disease, Ig
immunoglobulin, IL-10 interleukin-10, LOF loss-of-function, iNKT
invariant NKT cells, NK natural killer cells, Nl normal, sd syndrome,
SLE systemic lupus erythematous disease, Tc T cells, TCR T cell
receptor, XL X-linked transmission
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IV. Diseases of immune dysregulaon. b: Syndromes with Autoimmunity and Others
Syndromes with Autoimmunity
Increased CD4- CD8- TCR αβ+        (double negative (DN) T cells)   ?
Yes: 
ALPS 
Autoimmune
Lymphoproliferative Sd
Chronic adenopathy
Splenomegaly, defective 
lymphocyte apoptosis.
ALPS-FAS. TNFRSF6. AD or AR.
Autoimmune cytopenias,
increased lymphoma risk, IgG
and IgA Nl or increased, elevated
serum FasL, IL-10, vitamin B12.
ALPS-Caspase 8**. CASP8. AR.
Bacterial and viral infecons,
Hypogammaglobulinemia.
Defecve lymphocyte acvaon.
Slightly increased DNT cells.
ALPS-FASLG. TNFSF6.AR. 
Autoimmune cytopenias, SLE,
soluble FasL is not elevated
ALPS-Caspase10*. CASP10. AD.  
FADD deficiency.** FADD. AR. 
Funconal hyposplenism, 
bacterial and viral infecons, 
recurrent episodes of 
encephalopathy and liver 
dysfuncon. 
No : 
Regulatory T Cell Defects ?
Autoimmune polyendocrinopathy with candidiasis
and ectodermal dystrophy: APECED (APS-1) .
AIRE. AR/ AD. 
Hypoparathyroidism hypothyroidism, adrenal
insufficiency, diabetes, gonadal dysfuncon and
other endocrine abnormalies, chronic
mucocutaneous candidiasis, dental enamel
hypoplasia, alopecia, enteropathy, pernicious
anemia.
JAK1 GOF**. JAK1. AD GOF.
HSM, eosinophilic enteris, thyroid disease, poor
growth, viral infecons. Eosinophilia,
ITCH deficiency. ITCH. AR.
Early-onset chronic lung disease (intersal
pneumonis), thyroidis, type I diabetes, chronic
diarrhea/enteropathy, and hepas, developmental
delay, dysmorphic facial features .
Tripepdyl-Pepdase II Deficiency**. TPP2. AR.
Variable lymphoproliferaon, severe autoimmune
cytopenias, hypergammaglobulinemia, recurrent
infecons.
Decreased Tc and Bc.
IPEX, immune dysregulaon, polyendocrinopathy,
enteropathy X-linked. FOXP3. Autoimmune enteropathy,
early onset diabetes, thyroidis hemolyc anemia,
thrombocytopenia, eczema, elevated IgE, IgA. Lack and/or
impaired funcon of CD4+ CD25+ FOXP3+ regulatory T cells (Tregs).
CTLA4 deficiency (ALPSV). CTLA4. AD. Autoimmune
cytopenias, enteropathy, intersal lung disease, extra-lymphoid
lymphocyc infiltraon recurrent infecons . Impaired funcon
of Tregs. Tc and Bc decreased.
CD25 deficiency*. IL2RA. AR. Lymphoproliferaon,
autoimmunity, impaired Tc proliferaon. No CD4+C25+ cells
with impaired funcon of Tregs cells.
STAT3 GOF mutaon. STAT3. AD. Lymphoproliferaon, solid organ autoimmunity, recurrent infecons.
Enhanced STAT3 signaling, leading to increased Th17 cell differenaon, lymphoproliferaon and
autoimmunity. Decreased Tregs and impaired funcon. Tc and Bc decreased.
LRBA deficiency. LRBA. AR. Recurrent infecons,
inflammatory bowel disease, autoimmunity. Reduced IgG
and IgA in most. Low or normal numbers of Bc. Normal or
decreased CD4 numbers, Tc dysregulaon.
BACH2 deficiency. BACH2. AD. Lymphocyc colis, sinopulmonary infecons. Impaired memory Bc
development. Progressive Tc lymphopenia. 
Immune Dysregulaon
with Colis: IBD
IL-10 deficiency*. IL10. AR.
Folliculis, recurrent respiratory
diseases, arthris. No funconal IL-10
secreon.
IL-10R deficiency. AR. Folliculis,
recurrent respiratory diseases, arthris,
lymphoma.
IL10RA Leukocytes unresponsive to IL-
10.
IL10RB. Leukocytes unresponsive to
IL10, IL22, IL26, IL28A, IL28B, IL29
NFAT5 haploinsufficiency**. NFAT5.
AD. Recurrent Sinopulmonary
infecons. Decreased memory Bc and
plasmablasts.
No Yes
Prolidase deficiency. PEPD. AR.
Chronic skin ulcers, eczema, infecons. Auto-
anbodies common.
CD122 deficiency. IL2RB. Lymphoproliferaon, lymphadenopathy, HSM, AIHA, dermas, enteropathy. 
Hypergammaglobulinemia, recurrent viral (EBV, CMV) infecons
DEF6 deficiency*. DEF6. HSM, enteropathy, cardiomyopathy, recurrent infecons. Low Tc, low or normal Bc
FERMT1 deficiency. FERMT1. Dermatosis (congenital blistering, skin atrophy, photosensivity, skin fragility, 
and scaling). Intracellular accumulaon of IgG, IgM, IgA, and C3 in colloid bodies under the basement
membrane
TGFB1 deficiency*. TGFB1. AR. 
Recurrent viral infecons, microcephaly, 
and encephalopathy. Decreased T cell
proliferaon in response to an-CD3
RIPK1 deficiency*. RIPK1. AR. 
Reccurrent infecons, progressive 
polyarthris. Low Tc , low or nl Bc.
Fig. 4 (continued)
V. Congenital defects of phagocyte number, funcon, or both.      a : Neutropenia (without an-PMN )
No syndrome associatedSyndrome associated
GFI 1 deficiency (SCN2)**. GFI1. AD.
B/T lymphopenia
Elastase deficiency. (SCN1). ELANE. AD.
Suscepbility to MDS/leukemia. Severe congenital
neutropenia or cyclic neutropenia (perform CBC
twice weekly/ 4 weeks).
HAX1 deficiency (Kostmann Disease) (SCN3). HAX1.
AR. Cognive and neurological defects in paents
with defects in both HAX1 isoforms, suscepbility to
MDS/leukemia
G6PC3 deficiency (SCN4). G6PC3. AR. Structural heart defects, urogenital abnormalies, inner ear
deafness, and venous angiectasias of trunks and limbs. Affected foncons: Myeloid differenaon,
chemotaxis, O2- producon.
Glycogen storage disease type 1b. G6PT1. AR.
Fasng hypoglycemia, lacc acidosis, hyperlipidemia, hepatomegaly.
VPS45 deficiency (SCN5). VPS45. AR.
Extramedullary hematopoiesis, bone marrow fibrosis, nephromegaly.
G-CSF receptor deficiency*. CSF3R. AR.
Stress granulopoiesis disturbed
P14/LAMTOR2 deficiency**. LAMTOR2. AR.
Paral albinism, growth failure. Hypogammaglobulinemia, reduced CD8 cytotoxicity.
X-linked neutropenia/ myelodysplasia WAS GOF.
WAS. XL GOF.
Myeloid maturaon arrest, monocytopenia, variable
lymphoid anomalies .
Barth Syndrome (3-Methylglutaconic aciduria type II). TAZ. XL.
Cardiomyopathy, myopathy, growth retardaon.
Cohen syndrome. COH1. AR. Dysmorphism, mental retardaon, obesity, deafness.
Clericuzio syndrome (Poikiloderma with neutropenia). C16ORF57 (USB1). AR.
Renopathy, developmental delay, facial dysmorphism, poikiloderma.
JAGN1 deficiency. JAGN1. AR. Osteopenia. Myeloid maturaon arrest.
3-Methylglutaconic aciduria. CLPB. AR. Neurocognive developmental aberraons, microcephaly,
hypoglycemia, hypotonia, ataxia, seizures, cataracts, IUGR.
SMARCD2 deficiency*. SMARCD2. AR.
Developmental aberraons, bones defect, myelodysplasia
Shwachman-Diamond Syndrome. DNAJC21. AR. EFL1*. AR.
Pancytopenia, exocrine pancreac insufficiency. SBDS. AR. +chondrodysplasia
SRP54 deficiency*. SRP54. AD. Neutropenia and exocrine pancreac insufficiency .
WDR1 deficiency. WDR1. AR.
Poor wound healing, severe stomas, neutrophil nuclei herniate. Mild neutropenia.
HYOU1 deficiency**. HYOU1. AR. Hypoglycemia, inflammatory complicaons.
Neutropenia with combined immune deficiency *.
MKL1. AR.
Mild thrombocytopenia. Lymphopenia.
Specific granule deficiency*. CEBPE. AR. Neutrophils with bilobed nuclei. Chronic neutropenia.
Rac 2 def** . RAC2.                       Poor
wound healing. LAD phenotype
(leukocytosis).
V. Congenital defects of phagocyte.     b : Functional defects
Leukocyte adhesion deficiency 
Skin infections evolve to large ulcers.  
Leukocytosis with neutrophilia
(WBC > 25000)
LAD I . 
ITGB2
Delayed cord separation with 
omphalitis+++, no pus formation, lack 
of inflammation is observed in 
infection area. Periodontitis leads to 
early loss of teeth. Severity of the 
disease correlates with the degree of 
deficiency in CD18 (FCM). (WBC 
20,000–150,000 with 60–85 % 
neutrophils)
LAD II (Congenital disorder of 
glycosylation, type IIc)  SLC35C1
Recurrent infections. Mild LAD type 1 
features with hh-blood group, growth
retardation, developmental
delay , facial dysmorphism
(depressed nasal bridge).
LAD III   
FERMT3
Severe bacterial infections and
severe bleeding disorder. Platelet 
aggregation assay.
Papillon-Lefèvre . CTSC. 
Periodons, palmoplantar
hyperkeratosis in some paents
β-Actin . ACTB
Mental retardaon, short stature
Localized juvenile
periodontitis . 
FPR1. 
Periodontitis only
Pulmonary alveolar
proteinosis. 
CSF2RA, AR. CSF2RB*, 
XL.
Affected cells: Alveolar
macrophages. Affected
fonction: GM-CSF 
signaling
CGD: 
Early onset of severe and
recurrent infections affecting initially the natural barriers of  the organism  ( lungs, 
lymph nodes, skin), and eventually inner 
structures (liver, spleen, bones, brain, and 
+++ hepatic abscess). Autoinflammatory
phenotype, IBD
Granulomata obstructing respiratory, 
urinary or gastrointestinal tracts. 
Inflammatory bowel disease (Crohn’s like 
disease) and perianal disease : up to 30 %
Pathogens : typically catalase negative 
bacteria (S. aureus and gram-negative 
bacilli, Aspergillus, Candida); other: 
Burkholderia cepacia,Chromobacterium
violaceum, Nocardia, and invasive Serratia
marcescens. In developing countries, BCG 
: adverse effects in up to 20 %. 
Microscopic granulomas.
XL CGD:  CYBB (gp91phox)
NCF1 (p47phox) , AR
CYBA (p22phox), AR 
NCF4 (p40phox), AR
NCF2 (p67phox), AR 
CYBC1** , AR
GATA2 def. GATA2, AD. 
Susceptibility to 
Mycocbacteria, Papilloma
Viruses, Histoplasmosis, 
Lymphedema. Alveolar
proteinosis, 
myelodysplasia/ AML/ 
CMML . Multi lineage 
cytopenias. Low NK.
Abnormal
Syndrome associated No Syndrome associated:  
DHR  assay (or NBT test) ?
NormalCystic fibrosis. 
CFTR. AR. 
Pancreatic insufficiency, 
Respiratory infections, 
elevated sweat chloride
G6PD def Class I. G6PD. Infections.              
Fig. 5 Congenital defects of phagocyte number, function, or both. a
Neutropenia. b Functional defects of phagocytes. AD autosomal
dominant transmission, AML acute myeloid leukemia, AR autosomal
recessive transmission, BCG bacillus Calmette-Guerin, CD cluster of
differentiation, CGD chronic granulomatous disease, CMF flow
cytometry, CMML chronic myelomonocytic leukemia, def deficiency,
DHR dihydrorhodamine-1,2,3, GM-CSF granulocytes/monocytes
colony stimulation factor, GOF gain-of-function, IBD inflammatory
bowel disease, IUGR intrauterine growth retardation, LAD leukocyte
adhesion deficiency, MDS myelodysplasia, NBT nitroblue of
tetrazolium, NK natural killer cells, WBC white blood cells, XL: X-
linked transmission
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Predominant pathogens (S. pneumoniae, S. aureus and 
Pseudomonas aeruginosa). Non-invasive bacterial infecons (skin 
infecons and upper respiratory tract infecons). Improve with 
age.   Roune Usual screening tests are normal. Specific 
screening tests (lack of proinflammatory cytokine producon and 
CD62L shedding) :  available only in specialized clinical 
immunology laboratories.
IRAK4 def . IRAK4, AR
MyD88 def . MYD88, AR.
VI. Defects in Intrinsic and Innate immunity.     a : Bacterial and Parasic Infecons : 
Isolated congenital asplenia. 
Bacteremia (encapsulated bacteria). No spleen. 
RPSA, AD
HMOX*, AR. Hemolysis, nephris, inflammaon
Predisposion to 
Invasive Bacterial infecons (pyogens):
meningis, sepsis, arthris, osteomyelis and 
abscesses, oen in the absence of fever.
IRAK-1 def**. IRAK1, XL.
X-linked MECP2 deficiency-related syndrome due to a large de 
novo Xq28 chromosomal deleon encompassing both MECP2 and 
IRAK1
Predisposion to 
Mucocutaneous
Candidiasis (CMC)
Chronic Mucocutaneous
Candidiasis without ectodermal
dysplasia
IL-17RA deficiency.
IL17RA, AR 
Folliculis. Suscepbility to S. 
aureus (skin infecons) and 
chronic bacterial infecons.
STAT1 GOF. STAT1, AD 
various fungal, bacterial and viral
(HSV) infecons, autoimmunity
(thyroidis, diabetes, cytopenias),
enteropathy
CARD9 def. 
CARD9, AR.
Predisposion to 
INVASIVE Fungal 
Diseases. 
Invasive 
candidiasis
infecon, deep 
dermatophytoses, 
other invasive 
fungal infecons.
Trypanosomiasis
APOL1, AD
Trypanosomiasis.
Predisposion to Parasic and Fungal
infecons 
TIRAP def**. TIRAP, AR. 
Staphylococcal disease during childhood. 
ACT1 deficiency*. ACT1, AR.
Blepharis, folliculis and 
macroglossia.
IL-17F deficiency*.
IL17F, AD.  Folliculis. 
IL-17RC deficiency.
IL17RC, AR.
Others
Osteopetrosis. 
TNFRSF11A, PLEKHM1 AR.
TCIRG1, AR. + 
hypocalcemia
CLCN7, OSTM1, AR. + 
hypocalcemia, neurologic
features
SNX10, AR. + visual
impairment
TNFSF11, AR. + severe
growth retardaon
Hydradenis suppurava.
PSENEN, AD.
NCSTN, AD. + acne
PSEN, AD. + 
hyperpigmentaon
Acute liver failure due to 
NBAS def. NBAS, AR.
Fever induces liver failure
Acute necrozing
encephalopathy. RANBP2, 
AD.
Fever induces acute 
encephalopathy
IRF4 haploinsufficiency*. 
IRF4, AD.
Whipple’s disease
VI. Defects in Intrinsic and Innate immunity. b : MSMD and Viral infecon
Mendelian Suscepbility to mycobacterial disease (MSMD)
Severe phenotypes. Moderate phenotypes.
Complete IFNGR1 Def
and IFNGR2 Def : 
IFNGR1, IFNGR2. AR.
Serious disseminated 
BCG  and environmental 
mycobacterial infecons 
(so ssue, bone 
marrow, lungs, skin, 
bones and lymph nodes), 
Salmonella spp., Listeria
monocytogenes and 
viruses 
Dominant clinical
phenotype is Herpes 
simplex encephalis (HSE) 
during primary infecon 
with herpes simplex virus 
type 1 (HSV1), usually 
between 3 months and 6 
years of age. Incomplete 
clinical penetrance for all 
eologies listed here. 
Roune screening tests 
are normal. 
Specific tests examining 
the TLR3 pathway : 
marked decrease in the 
ability of paent’s
fibroblasts to produce IFN-
α and β in response to 
HSV1 infecon.
UNC93B1 (AR), TRAF3**
(AD), TICAM1 (TRIF)*
(AR,AD), TBK1* (AD), 
IRF3* (AD)
TLR3 (AD,AR), + severe 
pulmonary influenza, VZV
DBR1* (AR) +other viral 
infecons of the 
brainstem
Predominant suscepbility to viral infecon
Epidermodysplasia
verruciformis (HPV)
HPV (group B1) 
infecons and cancer of 
the skin
EVER1 def. TMC6.AR. 
EVER2 def. TMC8. AR. 
CIB1 def. CIB1. AR. 
WHIM (Warts,
Hypogammaglobuline
mia, infecons, myelo-
kathexis) sd
CXCR4 AD GOF.
Warts (HPV) infecon,
neutropenia, low B cell
number, hypogamma-
globulinemia.
Predisposion to 
Severe Viral Infecon
STAT1 Def  (AR LOF). STAT1.
(+ Mycobacteria)
IRF7 deficiency**. IRF7. AR.
IRF9 deficiency*. IRF9. AR.
Severe influenza disease. 
STAT2 deficiency*. STAT2. 
AR. Disseminated vaccine-
strain measles
IFNAR2 deficiency**.
IFNAR2 AR. Disseminated 
vaccine-strain measles, 
HHV6. No response to IFN-α.
CD16 deficiency*. FCGR3A. 
AR. Severe herpes viral 
infecons, parcularly VZV, 
EBV, and HPV. 
MDA5 deficiency (LOF)*. 
IFIH1. AR. Rhinovirus and 
other RNA viruses
Herpes simplex
Encephalis
Macrophage gp91 phox deficiency CYBB, XL
IRF8 deficiency, IRF8 AD
ISG15 Def, ISG15. AR. Brain calcificaon. 
IFNg producon defect.
IRF8 deficiency, IRF8 AR Mulple other infecous 
agents. Myeloproliferaon
RORγt deficiency*. RORC AR. Suscepbility to 
Candida. IFNg producondefect, 
complete absence of IL-17A/F-producing Tc
JAK1 (LOF)*, JAK1. AR. Suscepbility to viruses, 
urothelial carcinoma. ↓ IFNg producon.
With Suscepbility to Salmonella
IL-12 and IL-23 receptor b1 chain deficiency. 
IL12RB1 .AR. 
IL-12p40 (IL-12 and IL-23) def. IL12B .AR.
IL-12Rb2 deficiency**. IL12RB2. AR
IL-23R deficiency**. IL23R. AR.
STAT1 LOF STAT1(AD)
Paral IFNγR1, IFNGR1. AR.
Paral IFNγR2, IFNGR2.AR.
AD IFNGR1 IFNGR1. AD. Mycobacterial
osteomyelis
SPPL2a deficiency*. SPPL2A. AR.
Tyk2 deficiency, TYK2. AR. 
Suscepbility to viruses, +/- elevated IgE. mulple 
cytokine signaling defect. P1104A TYK2 
homozygosity MSMD or tuberculosis.
IFNAR1 deficiency*. IFNAR1
AR. Severe disease caused by 
Yellow Fever vaccine and 
Measles vaccine
RNA poymerase III def*.
POLR3A. POLR3C. POLR3F. 
AD. Severe VZV infecon.
IL-18BP def**. IL18BP. AR. 
Fulminant viral hepas
Fig. 6 Defects in intrinsic and innate immunity. a Bacterial and parasitic
infections. b MSMD and viral infection. AD autosomal dominant
transmission, AR autosomal recessive transmission, BCG bacillus
Calmette-Guerin, CD cluster of differentiation, CMC chronic
mucocutaneous candidiasis, EBV Epstein-Barr virus, GOF gain-of-
function, IFNg interferon gamma, HHV6 human herpes virus type 6,
HPV human papillomavirus, HSV herpes simplex virus, LOF loss-of-
function, MSMD Mendelian susceptibility to mycobacterial disease,
NK natural killer cells, RNA ribonucleic acid, sd syndrome, Tc T cells,
TLR3 Toll-like receptor type 3, VZV varicella zoster virus, XL X-linked
transmission
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T-cell lymphoma subcutaneous
panniculis-like (TIM3 deficiency). HAVCR2.
AR. Panniculis, HLH, polyclonal cutaneous
T cell infiltrates or T-cell lymphoma
VIIa. Auto-inflammatory disorders
OthersRecurrent inflammaon
Recurrent fever
Systemic inflammaon with urcaria rash
Familial Mediterranean Fever (FMF) *  
MEFV. AR or AD (Usually M694del variant)
DA: 1–4 days FA : Variable. 
Polyserosis, Abdominal pain, Arthris,
Amyloidosis. Erysipelas-like erythema.
Predisposes to vasculis and inflammatory
bowel disease .
Colchicine-responsive +++.
Mevalonate kinase def* (Hyper IgD sd). 
MVK. AR 
DA: 3–7 days FA: 1–2 monthly. 
Cervical adenopathy. Oral aphtosis.
Diarrhea. Mevalonate aciduria during
aacks. Leukocytosis with high IgD levels.
TNF receptor-associated periodic 
syndrome; TRAPS.  TNFRSF1A. AD. 
DA: 1-4 weeks FA : Variable
Prolonged fever. Serosis, rash, Periorbital
edema and conjuncvis.
Amyloidosis. Joint inflammaon.
Familial Cold Autoinflammatory Syndrome (CAPS) * .
NLRP3, NLRP12.  AD  GOF DA: 24-48H
Non-pruric urcaria, arthris, chills, fever and 
leukocytosis aer cold exposure. 
Muckle Wells syndrome (CAPS) * NLRP3. AD  GOF.
Ethnic group : North European
Connuous fever. Oen worse in the evenings. 
Urcaria, Deafness (SNHL), Conjuncvis, Amyloidosis. 
Neonatal onset mulsystem inflammatory disease 
(NOMID) or chronic infanle  neurologic cutaneous and 
arcular syndrome (CINCA) *. NLRP3. AD  GOF.
Neonatal onset rash, with connuous fever and 
inflammaon.  Asepc and chronic meningis, chronic
arthropathy. Mental retardaon, Sensorineural deafness. 
and Visual loss in some paents.
NLRC4-MAS (macrophage acvang 
syndrome)*. NLRC4.
AD GOF. Severe enterocolis and 
macrophage acvaon syndrome (HLH). 
Triggered by cold exposure. 
PLAID (PLCg2 associated anbody deficiency and 
immune dysregulaon), or APLAID*. PLC2G. AD GOF. 
Cold  Urcaria. Impaired humoral immunity. 
Hypogammaglobulinemia, autoinflammaon. 
NLRP1 deficiency*. NLRP1. AR.
Dyskeratosis, autoimmunity and arthris. 
COPA defect. COPA. AD 
Autoimmune inflammatory arthris and 
intersal lung disease with Th17 
dysregulaon and autoanbody producon
A20 haploinsufficiency TNFAIP3. AD LOF. Arthralgia, 
mucosal ulcers, ocular inflammaon.
NLRP1 GOF. NLRP1. AD GOF. 
Palmoplantar carcinoma, corneal scarring; 
recurrent respiratory papillomatosis. 
Increased IL1β.
ALPI deficiency*. ALP1. AR.
TRIM22 def*. TRIM22. AR
Inflammatory bowel disease.
CANDLE sd (chronic atypical neutrophilic
dermas with lipodystrophy). 
PSMB8, AR and AD. Contractures, 
panniculis, ICC, fevers. 
PSMG2, AR. Panniculis, lipodystrophy, 
AIHA.
(Variants in PSMB4, PSMB9, PSMA3, and POMP have 
been proposed to cause a similar CANDLE phenotype in 
compound heterozygous monogenic , digenic,and AD 
monogenic models).
Sterile inflammaon  ( skin / bone / joints )
VIIb. Auto-inflammatory disorders
CAMPS CARD14. AD. Psoriasis.
Progressive encephalopathy, ICC, Cerebral atrophy, HSMG,
leukodystrophy , Thrombocytopenia, Elevated hepac
transaminases . Chronic cerebrospinal fluid (CSF) lymphocytosis
Aicardi-Goueres Syndromes :
TREX1 AR-AD (+SLE, FCL), RNASEH2A, RNASEH2B (+SP),
RNASEH2C, SAMHD1 (+ FCL), ADAR1 (+BSN, SP), IFIH1 GOF AD (+
SLE, SP, SMS), DNASE2
Type 1  Interferonopathies
Spondyloenchondro-dysplasia with immune dysregulaon
(SPENCDI). ACP5.
Short stature, SP, ICC, SLE-like auto-immunity (Sjögren's
syndrome, hypothyroidism, inflammatory myosis, Raynaud's
disease and viligo), hemolyc anemia, thrombocytopenia,
skeletal dysplasia, possibly recurrent bacterial and viral infecons.
STING-associated vasculopathy, infanle-onset. TMEM173.
Early-onset inflammatory disease, Skin vasculopathy, inflammatory
lung disease, systemic autoinflammaon and ICC, FCL.
ADA2 deficiency. CECR1. Polyarteris nodosa, childhood-onset,
early-onset recurrent ischemic stroke and fever, Livedo racemosa,
some paents develop hypogammaglobulinemia
XL reculate pigmentary disorder. POLA1. Hyper-
pigmentaon, reculate paern. Inflammatory lung and
Gastroenterisor colis. Corneal scarring, characteriscfacies
USP18 def *. USP18. TORCH like syndrome.
Pyogenic sterile arthris, pyoderma
gangrenosum, acne (PAPA) syndrome, 
hyperzincemia and hyper-
calprotecnemia. PSTPIP1 (C2BP1). AD
DA:  5 days FA: Fixed interval : 4-6 weeks
Destrucve arthris, Pyoderma
gangrenosum, inflammatory skin rash,
Myosis. Acute-phase response during
aacks
Chronic recurrent mulfocal osteomyelis
and congenital dyserythropoiecanemia
(Majeed syndrome). LPIN2. AR
DA : Few days FA : 1-3 / month
Chronic recurrent mulfocal osteomyelis,
severe pain, tender so ssue swelling,
Transfusion-dependent anemia, cutaneous
inflammatory disorders
Blau syndrome. NOD2 (CARD15). AD.  
Connuous inflammaon.
Uveis, Granulomatous synovis, Camptodactyly, 
Rash, Cranial neuropathies, 30% develop Crohn
colis. Sustained modest acute-phase response.
ADAM17  deficiency*. ADAM17 . AR. 
Early onset diarrhea and skin lesions. Severe
bacteremia.
Defecve TNFα producon. 
Cherubism. SH3BP2.                                           
AR. 
Bone degeneraon in jaws
SLC29A3 mutaon. SLC29A3 . AR. 
Hyperpigmentaon hypertrichosis, hisocytosis-
lymphadenopathy plus syndrome 
DITRA. (Deficiency of IL-36 receptor antagonist). 
IL-36RN. AR . 
Life-threatening, mulsystemic inflammatory 
disease characterized by episodic widespread, 
pustular psoriasis, malaise, and leukocytosis.
DIRA (Deficiency of the Interleukin 1 
Receptor Antagonist) IL1RN. AR
Connuous inflammaon.
Neonatal onset of sterile mulfocal
osteomyelis, perioss and pustulosis. Otulipenia/ORAS*. OTULIN. AR. 
Neonatal onset of recurrent fever, Arthralgia, 
lipodystrophy. Dermas, diarrhea, Neutrophilia
Predominant on the skinPredominant on the bone / joints
AP1S3 deficiency*. AP1S3. AR. 
Pustular psoriasis
Pediatric systemic lupus erythematosus. DNASE1L3. Very 
early onset SLE, reduced complement levels, autoanbodies
(dsDNA, ANCA), lupus nephris, hypocomplementemic
urcarial vasculis syndrome.
OAS1 def*. OAS1. AD GOF. Pulmonary alveolar proteinosis, 
skin rash.
Fig. 7 a, b Autoinflammatory disorders. AD autosomal dominant
transmission, ANCA anti-neutrophilic cytoplasmic autoantibody, AR
autosomal recessive transmission, BSN bilateral striatal necrosis, CAPS
cryopyrin-associated periodic syndrome, DA duration of acute
inflammation episode, dsDNA double-stranded deoxyribonucleic acid,
FA frequency of acute inflammation episode, FCL familial chilblain
l u p u s , GOF g a i n - o f - f u n c t i o n , HLH hemoph a g o c y t i c
lymphohistiocytosis, HSM hepatosplenomegalia, ICC intracranial
calcifications, IL interleukin, LOF loss-of-function, sd syndrome, SLE
systemic lupus erythematosus, SMS Singleton-Merten syndrome,
SNHL sensorineural hearing loss, SP spastic paraparesis, TORCH
toxoplasmosis, other, rubella, cytomegalovirus, and herpes infections
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VIII. Complement deficiencies
C9 def. C9. 
Mild suscepbility.
Atypical Hemolyc 
Uremic Syndrome
Factor D 
def. 
CFD.  AR.
C1inhibitor. 
SERPING1.
AD, Hereditary 
angioedema. 
Spontaneous 
acvaon of the 
complement pathway 
with consumpon of 
C4/C2
Properdin
def. 
PFC. XL
C1s def.C1S. 
Mulple autoimmune diseases; 
Ehlers Danlos phenotype 
SLE-like syndrome. 
Infecons with encapsulated 
organisms
Absent CH50 hemolyc acvity
C2 def. C2. 
Vasculis, Polymyosis, 
atherosclerosis
C1q def.  C1QA, C1QB, C1QC. 
C1r def. C1R. Ehlers Danlos
phenotype 
Complete C4 def .
C4A+C4B.AR. 
Paral deficiency is common 
(either C4A or C4B) and appears 
to have a modest effect on host 
defense
MASP2 def. 
MASP2. AR.
Inflammatory lung 
disease, autoimmunity
Disseminated 
Neisserial infecons
C5 def. C5
C6 def. C6
C7 def . C7.
+ Vasculis
C8 def. 
C8A, C8B, C8G
Recurrent 
pyogenic
infecons
Membrane Aack 
Complex Inhibitor 
deficiency.
CD59. Hemolyc 
anemia. 
Polyneuropathy.
Ficolin 3 def.
FCN3. AR.
Infecons mainly in
the lungs; abscesses,
necrozing entero-
colis in infancy;
selecve anbody
defect to Pneumo-
coccal polysaccharides.
Absence of
complement acvaon
by the Ficolin 3
pathway
Suscepbility to infecons
High Low
Others
Factor B. CFB LOF.
AR. Infecons with
encapsulated
organisms. Deficient
acvaon of the
alternave pathway
C3 GOF. C3. AD.
Glomerulonephris. Increased acvaon of 
complementC3 LOF. C3. AR.
Absent CH50 and AH50
hemolyc acvity,
defecve opsonizaon
and humoral response
Factor B GOF. CFB. AD. Increased 
spontaneous AH50 
Factor H def. CFH. AR or AD. 
Infecons, disseminated neisserial
infecons, preeclampsia. Spontaneous 
acvaon of the alternave complement 
pathway with consumpon of C3
Thrombomodulin def. THBD. AD. 
Normal CH50, AH50
Factor I deficiency. AR. Infecons, 
disseminated neisserial infecons, 
preeclampsia. Spontaneous acvaon 
of the alternave complement 
pathway with consumpon of C3
Factor H –related protein 
deficiencies. CFHR1-5. 
AR or AD. Later onset, disseminated 
neisserial infecons. Normal CH50, AH50, 
autoanbodies to Factor H.
Membrane Cofactor Protein 
deficiency. CD46.AD,Glomerulone-
phris. Infecons, preeclampsia . Inhibitor 
of complement alternate pathway, 
decreased C3b binding
Absent CH50 and AH50 
hemolyc acvity. 
Defecve bactericidal 
acvity.
Normal CH50. 
Absent AH50 
hemolyc  
acvity
CD55 deficiency 
(CHAPLE disease). 
CD55. AR. Protein 
losing enteropathy, 
thrombosis
Periodontal Ehlers 
Danlos. C1R,C1S. 
AD GOF.
Hyperpigmentaon
skin fragility. 
Normal CH50.
Fig. 8 Complement deficiencies. AD autosomal dominant transmission,
AH50 alternate pathway hemolytic activity, AR autosomal recessive
transmission, CH50 complement hemolytic activity, def deficiency,
GOF gain-of-function, LOF loss-of-function, sd syndrome, SLE
systemic lupus erythematosus, XL X-linked transmission
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Dyskeratosis congenita :
IUGR, microcephaly, pulmonary and 
hepac fibrosis, nail dystrophy, sparse 
scalp hair and eyelashes; reculate skin 
pigmentaon; palmar hyperkeratosis; 
premalignant oral leukoplakia; 
pancytopenia; +/- recurrent infecons. 
DKC1: XL, Bc and Tc: Progressive 
decrease. 
NOLA2 (NHP2), NOLA3 (NOP10): AR, 
Tc: Decreased. RTEL1 : AD, Tc:
Decreased. TERC, TINF2, ACD : AD,Tc:
variable. TERT, TPP1: AD/AR, Tc:
variable. DCLRE1B/ SNM1/APOLLO, 
WRAP53*, DCAB1: AR,Tc: variable. 
Hoyeraal-Hreidarsson Syndrome (HHS) 
Severe phenotype with developmental 
delay and cerebellar hypoplasia.
AR, RTEL1, PARN, ACD 
Dyskeratosis congenita (DKC) 
Myelodysplasia, short telomeres.
Exclude other causes: 
Fanconi anemia, 
Blackfan-Diamond
COATS plus Sd: Intracranial 
calcificaon, abnormal telomeres, 
IUGR, gastrointesnal hemorrhage 
due to vascular ectasia, hypocellular
bone marrow. pancytopenia
STN1: premature aging, 
CTC1 : sparse graying hair, 
dystrophic nails, osteopenia, renal 
telangiectasia, 
MIRAGE sd ,AD. SAMD9 (GOF) : 
IUGR with gonadal abnormalies, 
adrenal failure, MDS with 
chromosome 7 aberraons, 
predisposion to infecons, 
enteropathy, absent spleen
Ataxia pancytopenia sd. AD.
SAMD9L. (GOF) :Cytopenia, 
predisposion to MDS with 
chromosome 7 aberraons and 
progressive cerebellar dysfuncon
IX. Bone marrow failure
Fanconi anemia  
CNS, skeletal, skin, 
cardiac, GI,
urogenital anomalies. 
Increased
chromosomal
breakage, 
pancytopenia.
Fanconi anemia Type 
A-W:
AR
FANCA, FANCC, 
BRCA2, FANCD2, 
FANCE, FANCF, 
XRCC9,FANCI, BRIP1, 
FANCL, FANCM, 
PALB2, RAD51C, 
SLX4,ERCC4, RAD51, 
BRCA1, UBE2T, XRCC2, 
MAD2L2,RFWD3, 
XL
FANCB
SRP72- deficiency**. 
SRP72,  AD
Bone marrow failure and congenital
nerve deafness
Bone marrow failure sd
(BMFS)
Myelodysplasia
BMFS5*
TP53,  AD
Erythroid hypoplasia,
B-cell deficiency
Others
Fig. 9 Bone marrow failure disorders. AD autosomal dominant
transmission, AR autosomal recessive transmission, Bc B cells, BMFS
bone marrow failure syndrome, CNS central nervous system, DKC
dyskeratosis congenita, GI gastrointestinal, GOF gain-of-function,
IUGR intrauterine growth retardation, MDS myelodysplasia, sd
syndrome, Tc T cells, XL X-linked transmission
Conclusion
This phenotypic classification of IEI forms a diagnostic re-
source, aimed to complement the 2019 IUIS genotypic clas-
sification. These figures serve as diagnostic orientation tools
for patients with any of the typical phenotypic presentations of
IEI, whether clinical or biological. They were designed for,
and will hopefully be useful to physicians and biologists who
are not experts in the field of IEI. We hope that these figures
can help them reach a diagnosis of IEI when encountering
patients whose clinical or biological phenotypes are evocative
of IEI.
Compliance with Ethical Standards
Conflict of Interest The authors declare that they have no conflict of
interest.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adap-
tation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes
were made. The images or other third party material in this article are
included in the article's Creative Commons licence, unless indicated oth-
erwise in a credit line to the material. If material is not included in the
article's Creative Commons licence and your intended use is not permitted
by statutory regulation or exceeds the permitted use, you will need to
obtain permission directly from the copyright holder. To view a copy of
this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Tangye SG, Al-Herz W, Bousfiha A,Chatila T, Cunningham-
Rundles C, Etzioni A, et al. Human Inborn Errors of Immunity:
2019 Update on the Classification from the International Union of
Immunological Societies Expert Committee. J Clin Immunol (2020).
https://doi.org/10.1007/s10875-019-00737-x
2. Bousfiha AA, Jeddane L, Ailal F, Benhsaien I, Mahlaoui N, Casanova
JL, et al. Primary immunodeficiency diseases worldwide: more com-
mon than generally thought. J Clin Immunol. 2013;33(1):1–7.
3. Bousfiha A, Jeddane L, Picard C, Ailal F, Gaspar HB, Al-Herz W,
et al. The 2017 IUIS phenotypic classification for primary immuno-
deficiencies. J Clin Immunol. 2018;38(1):129–43.
80 J Clin Immunol (2020) 40:66–81
X. Phenocopies of PID
Splenomegaly, lymphadenopathy,                                   
autoimmune cytopenias. Defective lymphocyte apoptosis. 
ALPS-SFAS 
(somatic mutations in TNFRSF6)/ ALPS-FAS  
(ALPS type Im)
RALD. RAS-associated autoimmune leukoproliferative
disease. (ALPS Like); N-RAS GOF, K-RAS GOF
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cytopenia, colitis, chronic diarrhea. No B cells. 
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